Bausch + Lomb Corporation
HealthcareNYSE:BLCO · New York Stock Exchange
-$0.20 today
Vol 0.23M · Avg 0.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.6%
avg -1.2%
ROIC
1.5%
avg 1.2%
ROA
-2.6%
avg -0.3%
Analysis
ROIC is currently the strongest return metric at 1.5% versus its period average of 1.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brenton L. Saunders | Chief Executive Officer & Chairman | $5.62M | — | 56 | $978,389.00 | 0.27% |
Osama A. Eldessouky | Executive Vice President & Chief Financial Officer | $1.79M | — | 54 | $343,192.00 | 0.10% |
A. Robert D. Bailey | Executive Vice President & Chief Legal Officer | $1.47M | — | 63 | $85,505.00 | 0.02% |
Yehia Hashad | Executive Vice President of Research & Development and Chief Medical officer | $1.44M | — | 58 | $166,377.00 | 0.05% |
Andrew Stewart | President of Global Pharmaceuticals & International Consumer | $1.25M | — | 50 | $86,656.00 | 0.02% |
George Gadkowski | Vice President & Head of Investor Relations & Business Insights | — | — | — | — | — |
Jonathon L. Kellerman | Chief Compliance Officer | — | — | — | — | — |
Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer | — | — | 66 | — | — |
Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer | — | — | 56 | $89,640.00 | 0.03% |
Crawford | Chief Communications Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$1.22M
Sells
0
$0.00
Net Sentiment
+$1.22M
Net buying
Most Active
Bailey A Robert D
1 transactions
Analysis
Insiders reported 9 buys worth $1.22M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.22M. Bailey A Robert D was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -63.0% | +70.3% (7yr)1 analysts |
| Revenue | N/A | N/A | -0.1% | +6.7% (7yr)5 analysts |
| Net Income | N/A | N/A | -72.8% | +94.4% (7yr)5 analysts |
| EBIT | N/A | N/A | -19.4% | +4.8% (7yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.1% over three years. Forward estimates point to Net Income at +94.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.48B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.59B
Glaukos Corporation
NYSE:GKOS
$7.45B
Oscar Health, Inc.
NYSE:OSCR
$7.31B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Teleflex Incorporated
NYSE:TFX
$5.78B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.82B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.98B
Who manages BLCO?
Bausch + Lomb Corporation (BLCO) lists 10 active executives. The top listed executive is A. Robert D. Bailey, Executive Vice President & Chief Legal Officer.
Are BLCO insiders buying or selling?
Recent insider activity shows net buying of $33.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.